C4 Therapeutics Reports Q2 2026 Results: Cash Runway to 2028, Cemsidomide Trials Advance
CCCC has more than doubled off its 52-week low of $1.69.
Summary
C4 Therapeutics reported Q2 2026 financials with $300.4M in cash, extending runway to end of 2028. Cemsidomide trials remain on track with data readouts in 2027. The company raised $33.5M via ATM and received $20M from Roche.
Key Events · Earnings and Guidance · CCCC
-
Cash Runway Extended to End of 2028
Cash, cash equivalents and marketable securities totaled $300.4M as of June 30, 2026, up from $297.1M at year-end 2025, driven by $33.5M in ATM proceeds and a $20M Roche upfront payment. Management expects this to fund operations through the end of 2028.
-
Cemsidomide Clinical Trials Advance
Phase 2 MOMENTUM trial enrollment on track for Q1 2027 with initial ORR data in H2 2027. Phase 1b combo with elranatamab to provide dose escalation update in H2 2026 and data from all cohorts in mid-2027. New Phase 1b combo trial with standard-of-care therapies to start in H1 2027.
-
Q2 2026 Financial Results Improve
Revenue was $6.6M (vs. $6.5M in Q2 2025). Net loss narrowed to $23.6M ($0.18/share) from $26.0M ($0.37/share) a year ago, driven by lower R&D and G&A expenses.
-
Roche DAC Collaboration Upfront Received
C4T entered a new collaboration with Roche in April 2026 to develop degrader-antibody conjugates, receiving a $20M upfront payment in May 2026.
Analysis · CCCC · Life Sciences
C4 Therapeutics delivered a solid quarter with $300.4M in cash, extending runway to end of 2028 — a critical survival signal for a clinical-stage biotech. The company raised $33.5M via its ATM program and received a $20M Roche upfront, bolstering its balance sheet. Cemsidomide, its lead asset, continues to show promise with multiple Phase 1b/2 trials advancing and data readouts expected in 2027. The net loss narrowed to $0.18/share from $0.37 a year ago, reflecting disciplined spending. This filing confirms the company is well-funded to reach key catalysts without near-term dilution risk.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CCCC was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $400.3M. The 52-week trading range was $1.69 to $5.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.